Evidence map›Paper›PMID 37284163›Full record

ArticleFree neuropathology2022

Neurodevelopmental disorders: 2022 update.

Miguel Sabariego-Navarro, Álvaro Fernández-Blanco, Cesar Sierra, Mara Dierssen

Open access · greenAbstract read
In one paragraph

Article in Free neuropathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Miguel Sabariego-NavarroCenter for Genomic Regulation, The Barcelona Institute for Science and Technology, Barcelona Spain.
Álvaro Fernández-BlancoCenter for Genomic Regulation, The Barcelona Institute for Science and Technology, Barcelona Spain.
Cesar SierraCenter for Genomic Regulation, The Barcelona Institute for Science and Technology, Barcelona Spain.
Mara DierssenCenter for Genomic Regulation, The Barcelona Institute for Science and Technology, Barcelona Spain.
Barcelona Institute of Science and Technology · ESUniversitat Pompeu Fabra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With a prevalence of 2-4% of the worldwide population, neurodevelopmental disorders (NDDs) comprise a heterogeneous group of disorders associated with neurodevelopmental dysfunction, including intellectual disability (ID), autism spectrum disorder (ASD), Down syndrome (DS) and attention-deficit/hyperactivity disorder (ADHD) among others. However, due to their heterogeneity and overlapping clinical features, NDDs such as ASD are often misdiagnosed, while for others with more distinct symptoms, such as Rett syndrome or DS, the mechanisms underlying their pathogenesis remain elusive. Last year, important steps in the mechanistic understanding of several NDDs have been achieved. New preclinical models demonstrated causality between

Indexed as

Aicardi-Goutières syndromeAutism spectrum disorderChromatin remodelerMitovesiclesRepeatometRNAs methylation

Identifiers

PMID37284163
PMCPMC10209850
OpenAlexW4379599211

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.